In this cohort, we found that diabetes, erythropoietin-stimulating agent use, dexamethasone use, and VTE history were independent predictors of IMiD-related VTE, which is in agreement with most previous studies, and our results are also in agreement with the IMWG guidelines for the risk variables correlated with IMiD-related VTE. Here, EPO is linked to diabetes mellitus.